These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 26833162)

  • 1. Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.
    Giandhari J; Basson AE; Sutherland K; Parry CM; Cane PA; Coovadia A; Kuhn L; Hunt G; Morris L
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2248-56. PubMed ID: 26833162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial.
    Sutherland KA; Parry CM; McCormick A; Kapaata A; Lyagoba F; Kaleebu P; Gilks CF; Goodall R; Spyer M; Kityo C; Pillay D; Gupta RK;
    PLoS One; 2015; 10(9):e0137834. PubMed ID: 26382239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy.
    McKinnon JE; Delgado R; Pulido F; Shao W; Arribas JR; Mellors JW
    Antivir Ther; 2011; 16(5):725-32. PubMed ID: 21817194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
    Nijhuis M; van Maarseveen NM; Lastere S; Schipper P; Coakley E; Glass B; Rovenska M; de Jong D; Chappey C; Goedegebuure IW; Heilek-Snyder G; Dulude D; Cammack N; Brakier-Gingras L; Konvalinka J; Parkin N; Kräusslich HG; Brun-Vezinet F; Boucher CA
    PLoS Med; 2007 Jan; 4(1):e36. PubMed ID: 17227139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
    Paulsen D; Liao Q; Fusco G; St Clair M; Shaefer M; Ross L
    AIDS Res Hum Retroviruses; 2002 Sep; 18(14):1011-9. PubMed ID: 12396453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
    Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
    J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014.
    Rojas Sánchez P; Prieto L; Jiménez De Ory S; Fernández Cooke E; Navarro ML; Ramos JT; Holguín Á;
    PLoS One; 2017; 12(3):e0173168. PubMed ID: 28350802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen.
    Ghosn J; Delaugerre C; Flandre P; Galimand J; Cohen-Codar I; Raffi F; Delfraissy JF; Rouzioux C; Chaix ML
    PLoS One; 2011; 6(9):e24798. PubMed ID: 21949754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients.
    Giandhari J; Basson AE; Coovadia A; Kuhn L; Abrams EJ; Strehlau R; Morris L; Hunt GM
    AIDS Res Hum Retroviruses; 2015 Aug; 31(8):776-82. PubMed ID: 25919760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir.
    Mo H; Lu L; Dekhtyar T; Stewart KD; Sun E; Kempf DJ; Molla A
    Antiviral Res; 2003 Aug; 59(3):173-80. PubMed ID: 12927307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lopinavir/ritonavir resistance in patients infected with HIV-1: two divergent resistance pathways?
    Champenois K; Baras A; Choisy P; Ajana F; Melliez H; Bocket L; Yazdanpanah Y
    J Med Virol; 2011 Oct; 83(10):1677-81. PubMed ID: 21755502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.
    Masquelier B; Breilh D; Neau D; Lawson-Ayayi S; Lavignolle V; Ragnaud JM; Dupon M; Morlat P; Dabis F; Fleury H;
    Antimicrob Agents Chemother; 2002 Sep; 46(9):2926-32. PubMed ID: 12183249
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Datir R; Kemp S; El Bouzidi K; Mlchocova P; Goldstein R; Breuer J; Towers GJ; Jolly C; Quiñones-Mateu ME; Dakum PS; Ndembi N; Gupta RK
    mBio; 2020 Nov; 11(6):. PubMed ID: 33144375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
    Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
    Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
    Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
    J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir.
    Sutherland KA; Ghosn J; Gregson J; Mbisa JL; Chaix ML; Cohen Codar I; Delfraissy JF; Delaugerre C; Gupta RK
    J Antimicrob Chemother; 2015 Jan; 70(1):243-8. PubMed ID: 25228587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.
    Torti C; Uccelli MC; Quiros-Roldan E; Gargiulo F; Tirelli V; Lapadula G; Regazzi M; Pierotti P; Tinelli C; De Luca A; Patroni A; Manca N; Carosi G
    J Clin Virol; 2006 Apr; 35(4):414-9. PubMed ID: 16280255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
    Prosperi MC; Zazzi M; Punzi G; Monno L; Colao G; Corsi P; Di Giambenedetto S; Meini G; Ghisetti V; Bonora S; Pecorari M; Gismondo MR; Bagnarelli P; Carli T; De Luca A;
    J Med Virol; 2010 Dec; 82(12):1996-2003. PubMed ID: 20981785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of drug-resistance in HIV-1 subtype C based on protease sequences from ART naive and first-line treatment failures in North India using genotypic and docking analysis.
    Toor JS; Sharma A; Kumar R; Gupta P; Garg P; Arora SK
    Antiviral Res; 2011 Nov; 92(2):213-8. PubMed ID: 21875619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
    J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.